Bimekizumab Phase 3 Psoriasis Study Demonstrates Superiority Versus Humira®
Go back to Bimekizumab Phase 3 Psoriasis Study Demonstrates Superiority Versus Humira®| (NYSE: UCB) | Delayed: 35.22 +0.11 (0.31%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $35.11 | 52 Week High | $ | |||
| Open | $35.25 | 52 Week Low | $ | |||
| Day High | $35.37 | P/E | N/A | |||
| Day Low | $34.98 | EPS | $ | |||
| Volume | 573,279 | |||||
| UCB Unsponsored ADR (AMEX: UCBJY) | Delayed: 128.49 -2.34 (1.79%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $130.83 | 52 Week High | $46.25 | |||
| Open | $127.81 | 52 Week Low | $32.74 | |||
| Day High | $129.05 | P/E | N/A | |||
| Day Low | $127.44 | EPS | $0.00 | |||
| Volume | 19,106 | |||||
